Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 20,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 20,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $26.75, for a total transaction of $535,000.00. Following the sale, the insider directly owned 745,188 shares in the company, valued at $19,933,779. This trade represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Enliven Therapeutics Stock Performance

ELVN opened at $27.03 on Friday. The company has a fifty day moving average of $20.36 and a two-hundred day moving average of $20.32. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -14.69 and a beta of 0.41. Enliven Therapeutics, Inc. has a fifty-two week low of $13.30 and a fifty-two week high of $29.98.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. On average, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

ELVN has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently modified their holdings of ELVN. Invesco Ltd. lifted its stake in shares of Enliven Therapeutics by 4.3% in the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after buying an additional 913 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Quantbot Technologies LP raised its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. Legal & General Group Plc lifted its stake in Enliven Therapeutics by 4.8% in the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock worth $691,000 after purchasing an additional 1,540 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after purchasing an additional 1,693 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.